Thompson Siegel & Walmsley LLC Sells 80,293 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Thompson Siegel & Walmsley LLC lowered its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 10.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 700,922 shares of the specialty pharmaceutical company’s stock after selling 80,293 shares during the quarter. Jazz Pharmaceuticals comprises approximately 1.3% of Thompson Siegel & Walmsley LLC’s holdings, making the stock its 9th largest holding. Thompson Siegel & Walmsley LLC’s holdings in Jazz Pharmaceuticals were worth $86,319,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Pacer Advisors Inc. increased its holdings in Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after purchasing an additional 278,465 shares in the last quarter. Cinctive Capital Management LP bought a new position in Jazz Pharmaceuticals in the third quarter valued at approximately $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after acquiring an additional 100,112 shares during the last quarter. GW&K Investment Management LLC grew its stake in shares of Jazz Pharmaceuticals by 26.6% during the fourth quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock worth $57,142,000 after buying an additional 97,589 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Jazz Pharmaceuticals by 501.4% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company’s stock worth $13,800,000 after purchasing an additional 93,422 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Activity

In other news, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Patricia Carr sold 1,140 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now owns 7,012 shares in the company, valued at approximately $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock valued at $4,022,825 in the last three months. 4.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on JAZZ shares. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Barclays reissued an “overweight” rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Finally, Robert W. Baird boosted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $190.53.

Jazz Pharmaceuticals Stock Down 2.0 %

JAZZ stock opened at $134.16 on Thursday. The firm has a 50 day moving average of $128.92 and a 200 day moving average of $120.49. The stock has a market capitalization of $8.15 billion, a PE ratio of 18.90, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.